Physician profile
Kyle Jones
NPI 1386179257
$1,658.68
in general payments reported to CMS, 2019-2025
11 companies · $634 in 2025
The $634 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.60 · 2023: $352 · 2024: $651 · 2025: $634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,586 · Education: $32.27 · Long Term Medical Supply Or Device Loan: $19.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,585.83 |
| Education | $32.27 |
| Long Term Medical Supply Or Device Loan | $19.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $400.60 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Viiv Healthcare Company | $323.19 | 2023-2024 | Apretude, Dovato, Rukobia |
| Gilead Sciences, INC. | $268.67 | 2023-2025 | Descovy |
| Abbott Laboratories | $165.97 | 2024-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Dexcom, INC. | $152.09 | 2023-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $136.33 | 2024-2025 | Pifeltro, Capvaxive, Delstrigo |
| Abbvie INC. | $91.00 | 2024 | |
| Verity Pharmaceuticals INC. | $62.94 | 2024-2025 | Tlando |
| Lilly USA, LLC | $21.90 | 2023 | Mounjaro |
| Pfizer INC. | $20.60 | 2021 | |
| Tolmar, INC. | $15.39 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.